Evidence map›Paper›PMID 38374232›Full record

ArticleScientific reports2024

Clemastine and metformin extend the window of NMDA receptor surface expression in ageing oligodendrocyte precursor cells.

Yasmine Kamen, Kimberley Anne Evans, Sergey Sitnikov, Sonia Olivia Spitzer, Omar de Faria, Mert Yucel, Ragnhildur Thóra Káradóttir

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. The Many Lives of an Oligodendrocyte Precursor Cell.Annual review of neuroscience · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Yasmine KamenCambridge Stem Cell Institute and Department of Veterinary Medicine, University of Cambridge, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge Biomedical Campus, Cambridge, CB2 A0W, UK. yk352@cam.ac.uk.ORCID 0000-0003-1867-7397
Kimberley Anne EvansCambridge Stem Cell Institute and Department of Veterinary Medicine, University of Cambridge, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge Biomedical Campus, Cambridge, CB2 A0W, UK.
Sergey SitnikovCambridge Stem Cell Institute and Department of Veterinary Medicine, University of Cambridge, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge Biomedical Campus, Cambridge, CB2 A0W, UK.
Sonia Olivia SpitzerCambridge Stem Cell Institute and Department of Veterinary Medicine, University of Cambridge, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge Biomedical Campus, Cambridge, CB2 A0W, UK.
Omar de FariaCambridge Stem Cell Institute and Department of Veterinary Medicine, University of Cambridge, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge Biomedical Campus, Cambridge, CB2 A0W, UK.
Mert YucelCambridge Stem Cell Institute and Department of Veterinary Medicine, University of Cambridge, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge Biomedical Campus, Cambridge, CB2 A0W, UK.ORCID 0000-0002-9344-0616
Ragnhildur Thóra KáradóttirCambridge Stem Cell Institute and Department of Veterinary Medicine, University of Cambridge, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge Biomedical Campus, Cambridge, CB2 A0W, UK. rk385@cam.ac.uk.ORCID 0000-0001-9675-2722
Wellcome/MRC Cambridge Stem Cell Institute · GBUniversity of Iceland · IS

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) No 771411Multiple Sclerosis Society (MS Society) 132RCUK | Medical Research Council (MRC) MC_PC_17230Wellcome Trust (Wellcome) 102160/Z/13/ZWellcome Trust (Wellcome) 203151/A/16/ZWellcome Trust (Wellcome) 203151/Z/16/ZWellcome Trust (Wellcome) 218481/Z/19/Z
6 · The paper itself

Abstract

In the central nervous system, oligodendrocyte precursor cells (OPCs) proliferate and differentiate into myelinating oligodendrocytes throughout life, allowing for ongoing myelination and myelin repair. With age, differentiation efficacy decreases and myelin repair fails; therefore, recent therapeutic efforts have focused on enhancing differentiation. Many cues are thought to regulate OPC differentiation, including neuronal activity, which OPCs can sense and respond to via their voltage-gated ion channels and glutamate receptors. However, OPCs' density of voltage-gated ion channels and glutamate receptors differs with age and brain region, and correlates with their proliferation and differentiation potential, suggesting that OPCs exist in different functional cell states, and that age-associated states might underlie remyelination failure. Here, we use whole-cell patch-clamp to investigate whether clemastine and metformin, two pro-remyelination compounds, alter OPC membrane properties and promote a specific OPC state. We find that clemastine and metformin extend the window of NMDAR surface expression, promoting an NMDAR-rich OPC state. Our findings highlight a possible mechanism for the pro-remyelinating action of clemastine and metformin, and suggest that OPC states can be modulated as a strategy to promote myelin repair.

Indexed as

MetforminOligodendrocyte Precursor CellsCell DifferentiationClemastineMyelin SheathOligodendrogliaReceptors, N-Methyl-D-AspartateClemastineMetforminReceptors, N-Methyl-D-Aspartate

Identifiers

PMID38374232
PMCPMC10876931
OpenAlexW4391941424

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.